Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 8Lymphoid 8Genitourinary 7Breast 6Other solid neoplasm 3Other hematologic neoplasm 3Head & Neck 3Dermatologic 3CNS 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Gynecologic 2

Conditions

Recurrence 1Neuroblastoma 1Neoplasms 1Lymphoma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pharmaceutical Preparations × CNS × Clear all
NCT07431216 2026-03-30

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Starlight Therapeutics Inc.

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Glioblastoma

NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT07334301 2026-01-12

BEACON2

University of Birmingham

Phase 1/2 Recruiting
160 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡